An important step towards a new analgesic strategy: the Metapain Phase III clinical trial has enrolled its first patients.
Aptys Pharmaceuticals and Unither Pharmaceuticals, two companies engaged in the development of pain management for the treatment of pain, announce the enrolment of the first patients in their Metapain® clinical trial in France.
Metapain® is a phase III interventional, multi-centre, randomised, double-blind study.
Four hundred patients will be enrolled in four countries: France, UK, Belgium and Russia.
The main objective is to evaluate the efficacy of a single oral administration of the fixed combination
nefopam/parac tamol compared to nefopam and paracetamol alone in patients with
with moderate to severe pain after impacted wisdom teeth extraction.
“We are delighted with the launch of our Phase III study. It is the result of a close collaboration between our two companies collaboration between our two companies,” said Éric Goupil and François Boutignon, respectively Chairman of Unither Pharmaceuticals and Aptys Pharmaceuticals. of Unither Pharmaceuticals and Aptys Pharmaceuticals respectively.
“We are convinced that Metapain® will be a success and offer patients a much needed alternative to opioid painkillers. to opioid analgesics in the pain management arsenal”.
Metapain®, for the oral treatment of moderate to severe pain.
Metapain® is a fixed combination of nefopam and paracetamol, two known non-opioid and non-anti-inflammatory molecules and non-anti-inflammatory molecules. They have already been combined for years in infusion for the treatment of postoperative pain. Several published pre-clinical and clinical studies have shown a synergistic effect of of these two molecules.
The combination of two non-opioid analgesics with complementary mechanisms of action will make Metapain® a reference treatment for moderate to severe pain.